These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 19264554)

  • 41. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
    Ghalayini IF; Al-Ghazo MA
    Neurourol Urodyn; 2007; 26(4):531-536. PubMed ID: 17330289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
    Krhut J; Samal V; Nemec D; Zvara P
    Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients.
    Deffontaines-Rufin S; Weil M; Verollet D; Peyrat L; Amarenco G
    Int Braz J Urol; 2011; 37(5):642-8. PubMed ID: 22099277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury.
    Chen SF; Jiang YH; Jhang JF; Kuo HC
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey].
    Peyronnet B; Sanson S; Amarenco G; Castel-Lacanal E; Chartier-Kastler E; Charvier K; Damphousse M; Denys P; de Seze M; Egon G; Even A; Forin V; Karsenty G; Kerdraon J; le Normand L; Loche CM; Manunta A; Mouracade P; Phe V; Previnaire JG; Ruffion A; Saussine C; Schurch B; Game X;
    Prog Urol; 2015 Dec; 25(17):1219-24. PubMed ID: 26318394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
    Álvares RA; Araújo ID; Sanches MD
    BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis.
    Elizondo RA; Karmonik C; Boone TB; Khavari R
    BMJ Open; 2017 Feb; 7(2):e013225. PubMed ID: 28159850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study.
    Ringoir A; Dhondt B; De Bleser E; Van Laecke E; Everaert K; Groen LA; Hoebeke P; Spinoit AF
    J Pediatr Urol; 2020 Apr; 16(2):181.e1-181.e8. PubMed ID: 31964616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
    Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
    Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany.
    Wefer B; Ehlken B; Bremer J; Burgdörfer H; Domurath B; Hampel C; Kutzenberger J; Seif C; Sievert KD; Berger K; Pannek J
    World J Urol; 2010 Jun; 28(3):385-90. PubMed ID: 19693509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Botulinum toxin for the management of bladder dysfunction.
    Schurch B
    Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
    Alvares RA; Silva JA; Barboza AL; Monteiro RT
    Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Harris MA; Harding C; Fulford S; Whiteway J
    BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
    [No Abstract]   [Full Text] [Related]  

  • 58. Botulinum toxin therapy for neurogenic detrusor overactivity.
    Smaldone MC; Ristau BT; Leng WW
    Urol Clin North Am; 2010 Nov; 37(4):567-80. PubMed ID: 20955908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia.
    Sekerci CA; Tanidir Y; Garayev A; Akbal C; Tarcan T; Simsek F
    Urology; 2018 Jan; 111():168-175. PubMed ID: 28943369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.